SynthesisLupus science & medicine2026
Measurement of haemolytic anaemia in a novel treatment response measure for SLE clinical trials.
Synthesis in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab.Lupus science & medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo define a clinically meaningful treatment response definition for haemolytic anaemia, that will form part of a novel multidomain outcome measure for SLE clinical trials.
methodsAn international working group comprising 12 clinicians and 4 patients completed a multistep consensus process. First, the scope of haemolytic anaemia for the SLE clinical trial context was defined. Candidate response measures were then nominated via an online survey and shortlisted for evaluation via a systematic literature review (SLR) focussing on relevant measurement properties and clinical trial utility. Informed by the SLR results, the working group used nominal group technique (NGT) to reach consensus on a response measure, as well as entry, clinically meaningful response and complete response thresholds.
resultsThe domain scope was unanimously agreed on as 'immune-mediated haemolytic anaemia attributed to active lupus that impacts the patient and is modifiable by therapy to reduce or control disease activity', including Coombs' positive autoimmune haemolytic anaemia and rarer subtypes. Six laboratory measures to fit this scope were shortlisted for the SLR, which screened 1519 articles, of which 10 were included. Consensus via NGT was reached on haemoglobin (Hb) improvement to measure haemolytic anaemia treatment response. Thresholds were defined for entry (Hb <100 g/L with laboratory confirmation of haemolysis), minimum clinically meaningful response (Hb improvement >20 g/L or Hb normalised with ongoing haemolysis) and complete response (Hb normalised without haemolysis).
conclusionsHb, with meaningful thresholds for entry and improvement, will be adopted to classify haemolytic anaemia treatment response in a novel multi-domain outcome measure for SLE clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.